Dopaminergic and serotonergic receptor function in the CNS

Perspectives in Psychiatric Care

Volumn 37, Issue 2, 2001, Pages 65-68

  Keltner, Norman L ^a   Hogan, Beverly ^a   Guy, Dena M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039568995     PISSN: 00315990     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2001.tb00620.x     Document Type: Article

References (25)

1. Barnes, N.M., & Sharp, T. (1999). A review of central 5HT receptors and their function. Neuropharmacology, 38, 1083-1152.
2. Bezchlibnyk-Butler, K.Z., & Jeffries, J.J. (1997). Clinical handbook of psychotropic drugs. Seattle: Hogrefe & Huber.
3. Blin, O. (1999). A comparative review of new antipsychotics. Canadian Journal of Psychiatry, 44, 235-244.
4. Calne, D.B. (1993). Treatment of Parkinson's disease. New England Journal of Medicine, 329, 1021-1030.
5. Camilleri, M., Northcutt, A.R., Kong, S., Dukes, G.E., McSorley, D., & Mangel, A.W. (2000). Efficacy and safety of alosetron in women with irritable bowel syndrome. Lancet, 355 (9209), 1030-1031.
6. Civelli, O., Bunzow, J.R., & Grandy, D.K. (1993). Molecular diversity of the dopamine receptors. Annual Review of Pharmacologic Toxicology, 32, 281-307.
7. Coccaro, E.G. (1989). Central serotonin and impulsive aggression. British Journal of Psychiatry, 155(Suppl. 8), 52-62.
8. Cowen, P.T. (1991). Serotonin receptor subtypes: Implications for psychopharmacology. British Journal of Psychiatry, 159(Suppl. 12), 7-14.
9. Dubovsky, S.L. (1994). Beyond the serotonin reuptake inhibitors: Rationale for the development of new serotonergic agents. Journal of Clinical Psychiatry, 55(Suppl.), 34-44.
10. Faris, P.L., Kim, S.W., Meller, W.H., Goodale, R.L., Oakman, S.A., Hofbauer, R.D., Marshall, A.M., Daughters, R.S., Banerjee-Stevens, D., Eckert, E.D., & Hartman, B.K. (2000). Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa. Lancet, 355(9206), 792-797.
11. Grahame-Smith, D.G. (1992). Serotonin in affective disorders. International Clinical Psychopharmacology, 6(Suppl. 4), 5-132.
12. Hertel, P., Fagerquist, M.V., & Svensson, T.H. (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha-2 adrenoreceptor blockade. Science, 286, 105-107.
13. Ito, H., Halldin, C., & Farde, L. (1999). Localization of 5HT1A receptors in the living human brain using [carbonyl-11C] WAY-100635. Journal of Nuclear Medicine, 40(1), 102-109.
14. Keltner, N.L. (2000). Neuroreceptor function and psychopharmacological response. Issues in Mental Health Nursing, 22(1), 31-50.
15. Keltner, N.L., & Folks, D.G. (2001). Psychotropic drugs (3rd ed.). St. Louis: Mosby.
16. Landry, M.J. (1994). Serotonin and impulsivity dyscontrol: Brain chemistry involved in impulse and addictive behavior. Behavioral Health Management, 14, 35-38.
17. Lehne, R.A. (2001). Pharmacology for nursing care (4th ed). Philadelphia: Harcourt.
18. Leonard, B.E. (1992). Subtypes of serotonin receptors: Biochemical changes and pharmacological consequences. International Journal of Psychopharmacology, 7, 13-21.
19. Lopez-Ibor, J.L. (1988). The involvement of serotonin in psychiatric disorders and behaviour. British Journal of Psychiatry, 153(Suppl.), S40-S54.
20. Meltzer, H. (1989). Serotonergic dysfunction in depression. British Journal of Psychiatry, 155(Suppl. 8), 25-31.
21. Perry, C.M., & Markham, A. (1998). Sumatriptan: An updated review in its use in migraine. Drugs, 55, 889-922.
22. Seeman, P., & Van Tol, H.H.M. (1994). Dopamine receptor pharmacology. Trends in Pharmacological Science, 15(7), 64-70.
23. Stahl, S.M. (1998). Basic psychopharmacology of antidepressants. Part I. Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry, 59(Suppl. 4), 5-14.
24. Starr, C. (1998). Emerging migraine treatments. Patient Care Nurse Practitioner, 1, 10-26.
25. Taubes, G. (1994). Will new dopamine receptors offer a key to schizophrenia? Science, 265, 1034-1035.